Shree Ganesh Biotech (India) announces Q1 results: Profit Rises by 60% YoY

The comprehensive analytics outlining the performance and outlook of Shree Ganesh Biotech (India) Limited‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Shree Ganesh Biotech (India) Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -56.92 %. However, it did see a marginal slip of -6 % from the previous quarter. Expenses decreased slightly by -14.19 % quarter-on-quarter, aligning with the annual decline of -54.44 %. Operating profit, while down -186.67 % compared to last year, faced a quarter-on-quarter increase of 75 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -5.48 %, but an expansion of 10.09 % sequentially. Other income fell by -65.06 % compared to the last quarter, Profit before tax grew annually by 60 % but saw a reduction from the preceding quarter by -55.56 %.
Net profit rose by 60 % year-on-year but witnessed a -55.56 % contraction from the last quarter. but a quarterly rise of 0 %. In summary, Shree Ganesh Biotech (India) Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Shree Ganesh Biotech (India) Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -56.92 % year-on-year, although there was a slight dip of -6 % from the previous quarter. Expenses decreased by -54.44 % compared to the previous year, with a decrease of -14.19 % quarter-on-quarter. Operating Profit dropped by -186.67 % annually, and saw a 75 % increase from the last quarter.
Net Profit showed yearly increase of 60 %, and experienced a -55.56 % decrease from the previous quarter. however rose by 0 % compared to the last quarter. In essence, while Shree Ganesh Biotech (India) Limited faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.